{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:08:49Z","timestamp":1788534529280,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP1DA056106"],"award-info":[{"award-number":["DP1DA056106"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.idc.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T11:53:40Z","timestamp":1719921220000},"page":"599-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["HIV and Substance Use Disorders"],"prefix":"10.1016","volume":"38","author":[{"given":"Audun J.","family":"Lier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adati","family":"Tarfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela V.","family":"Shenoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.idc.2024.06.003_bib2","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","article-title":"Infectious Diseases and Injection Drug Use: Public Health Burden and Response","volume":"222","author":"Levitt","year":"2020","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2024.06.003_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014\u20132015","volume":"375","author":"Peters","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2024.06.003_bib5","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6810a6","article-title":"Notes from the field: HIV diagnoses among persons who inject drugs\u2014Northeastern Massachusetts, 2015\u20132018","volume":"68","author":"Cranston","year":"2019","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"16","key":"10.1016\/j.idc.2024.06.003_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.15585\/mmwr.mm6916a2","article-title":"Notes from the field: outbreak of human immunodeficiency virus infection among persons who inject drugs - Cabell County, West Virginia, 2018-2019","volume":"69","author":"Atkins","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2024.06.003_bib7","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1093\/infdis\/jiaa112","article-title":"Responding to outbreaks of human immunodeficiency virus among persons who inject drugs-United States, 2016-2019: perspectives on recent experience and lessons learned","volume":"222","author":"Lyss","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2024.06.003_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12879-015-0913-0","article-title":"Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis","volume":"15","author":"Azar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idc.2024.06.003_bib9","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder: treatment improvement protocol (TIP) series 63, full document. HHS Publication No.18-5063 FULLDOC. 2021. Available at: https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf. Accessed November 28, 2023."},{"issue":"3","key":"10.1016\/j.idc.2024.06.003_bib10","doi-asserted-by":"crossref","first-page":"37517","DOI":"10.52965\/001c.37517","article-title":"Buprenorphine and its formulations: a comprehensive review","volume":"10","author":"Poliwoda","year":"2022","journal-title":"Health Psychol Res"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13011-019-0240-3","article-title":"The prevalence of alcohol use disorders among people living with HIV\/AIDS: a systematic review and meta-analysis","volume":"14","author":"Duko","year":"2019","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"10.1016\/j.idc.2024.06.003_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.drugalcdep.2010.06.014","article-title":"A\u00a0systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization","volume":"112","author":"Azar","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.idc.2024.06.003_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.idc.2024.06.003_bib14","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.mayocp.2020.01.030","article-title":"Evidence-based pharmacotherapies for alcohol use disorder: clinical pearls","volume":"95","author":"Fairbanks","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.idc.2024.06.003_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugalcdep.2014.03.025","article-title":"Stimulant use and HIV disease management among men in same-sex relationships","volume":"139","author":"Carrico","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.idc.2024.06.003_bib17","doi-asserted-by":"crossref","first-page":"e0234809","DOI":"10.1371\/journal.pone.0234809","article-title":"Treatment of stimulant use disorder: a systematic review of reviews","volume":"15","author":"Ronsley","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.idc.2024.06.003_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/10901981221148966","article-title":"Can contingency management solve the problem of adherence to antiretroviral therapy in drug-dependent individuals?","volume":"50","author":"Ribeiro","year":"2023","journal-title":"Health Educ Behav"},{"key":"10.1016\/j.idc.2024.06.003_bib19","doi-asserted-by":"crossref","first-page":"108230","DOI":"10.1016\/j.drugalcdep.2020.108230","article-title":"Abstinence-reinforcing contingency management improves HIV viral load suppression among HIV-infected people who use drugs: A randomized controlled trial","volume":"216","author":"Cunningham","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.idc.2024.06.003_bib20","doi-asserted-by":"crossref","first-page":"e1002715","DOI":"10.1371\/journal.pmed.1002715","article-title":"Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis","volume":"15","author":"De Crescenzo","year":"2018","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.idc.2024.06.003_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s40617-022-00730-8","article-title":"Feasibility, acceptability, and preliminary efficacy of a smartphone-based contingency management intervention for buprenorphine adherence","volume":"16","author":"DeFulio","year":"2023","journal-title":"Behav Anal Pract"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0376-8716(92)90005-W","article-title":"Benzodiazepine use and HIV risk-taking behaviour among injecting drug users","volume":"31","author":"Darke","year":"1992","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsat.2014.07.013","article-title":"Prescription medication misuse among HIV-infected individuals taking antiretroviral therapy","volume":"48","author":"Newville","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17512433.1.1.115","article-title":"Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice","volume":"1","author":"Bruce","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.idc.2024.06.003_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2024.06.003_bib27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1086\/503259","article-title":"Club drugs and HIV infection: a review","volume":"42","author":"Colfax","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.idc.2024.06.003_bib28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0000000000000786","article-title":"Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety","volume":"29","author":"Bracchi","year":"2015","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.idc.2024.06.003_bib29","doi-asserted-by":"crossref","first-page":"ofab289","DOI":"10.1093\/ofid\/ofab289","article-title":"A\u00a0Systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2024.06.003_bib30","doi-asserted-by":"crossref","first-page":"108852","DOI":"10.1016\/j.jsat.2022.108852","article-title":"Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder","volume":"142","author":"Lier","year":"2022","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-019-00436-7","article-title":"Medications for treatment of opioid use disorder among persons living with HIV","volume":"16","author":"Fanucchi","year":"2019","journal-title":"Curr HIV AIDS Rep"},{"issue":"5","key":"10.1016\/j.idc.2024.06.003_bib32","doi-asserted-by":"crossref","first-page":"e38335","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2024.06.003_bib34","first-page":"345","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/QAI.0000000000001759","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial","volume":"79","author":"Springer","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2024.06.003_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2017.01.026","article-title":"Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community","volume":"174","author":"Springer","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.idc.2024.06.003_bib38","doi-asserted-by":"crossref","first-page":"e2221346","DOI":"10.1001\/jamanetworkopen.2022.21346","article-title":"Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use","volume":"5","author":"Streed","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.idc.2024.06.003_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/JAN.0000000000000522","article-title":"An assessment of HIV risk, perceptions of risk, and potential adherence to preexposure prophylaxis among HIV-negative people with injection drug use who access mobile outreach services","volume":"34","author":"Champion","year":"2023","journal-title":"J\u00a0Addict Nurs"},{"issue":"13","key":"10.1016\/j.idc.2024.06.003_bib40","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1007\/s11606-023-08040-7","article-title":"provider implicit bias in prescribing HIV pre-exposure prophylaxis (PrEP) to people who inject drugs","volume":"38","author":"Dubov","year":"2023","journal-title":"J\u00a0Gen Intern Med"},{"issue":"7","key":"10.1016\/j.idc.2024.06.003_bib41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2024.06.003_bib42","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1007\/s10461-020-02800-w","article-title":"Real-world eligibility for HIV pre-exposure prophylaxis among people who inject drugs","volume":"24","author":"Picard","year":"2020","journal-title":"AIDS Behav"},{"issue":"9","key":"10.1016\/j.idc.2024.06.003_bib43","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.idc.2024.06.003_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11904-022-00619-9","article-title":"Measuring and addressing stigma within HIV interventions for people who use drugs: a scoping review of recent research","volume":"19","author":"Lancaster","year":"2022","journal-title":"Curr HIV AIDS Rep"},{"issue":"5","key":"10.1016\/j.idc.2024.06.003_bib46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11904-023-00667-9","article-title":"Integrated care models: HIV and substance use","volume":"20","author":"Hill","year":"2023","journal-title":"Curr HIV AIDS Rep"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2020.2559","article-title":"Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the national academies of sciences, engineering, and medicine","volume":"324","author":"Springer","year":"2020","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2024.06.003_bib48","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1093\/infdis\/jiz673","article-title":"Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's Advocacy Agenda","volume":"222","author":"Springer","year":"2020","journal-title":"J\u00a0Infect Dis"},{"issue":"16","key":"10.1016\/j.idc.2024.06.003_bib49","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2024.06.003_bib50","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.ypmed.2019.105779","article-title":"Sexual risk behaviors and STDs among persons who inject drugs: A national study","volume":"126","author":"Brookmeyer","year":"2019","journal-title":"Prev Med"},{"issue":"5","key":"10.1016\/j.idc.2024.06.003_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M18-1203","article-title":"Integrating treatment at the intersection of opioid use disorder and infectious disease epidemics in medical settings: a call for action after a national academies of sciences, engineering, and medicine workshop","volume":"169","author":"Springer","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12939-020-1135-7","article-title":"Mobile health clinics in the United States","volume":"19","author":"Malone","year":"2020","journal-title":"Int J Equity Health"},{"issue":"1","key":"10.1016\/j.idc.2024.06.003_bib53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12879-022-07354-x","article-title":"Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons","volume":"22","author":"Springer","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2024.06.003_bib54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/421392","article-title":"Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community","volume":"38","author":"Springer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2024.06.003_bib56","article-title":"Expanding harm reduction services and implementation of syringe services programs (SSP) within veterans health administration (VHA)","year":"2023","journal-title":"Veterans Health Administration"},{"key":"10.1016\/j.idc.2024.06.003_bib57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.drugalcdep.2018.05.032","article-title":"A\u00a0novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: a pilot study","volume":"190","author":"Ochalek","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.idc.2024.06.003_bib58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/14614448231158653","article-title":"mHealth and social mediation: mobile support among stigmatized people living with HIV and substance use disorder","volume":"25","author":"Yang","year":"2023","journal-title":"New Media Soc"},{"issue":"6","key":"10.1016\/j.idc.2024.06.003_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/apc.2017.0303","article-title":"PositiveLinks: A mobile health intervention for retention in HIV care and clinical outcomes with 12-month follow-up","volume":"32","author":"Dillingham","year":"2018","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"10.1016\/j.idc.2024.06.003_bib60","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10461-018-02389-1","article-title":"Use of an mHealth intervention to improve engagement in HIV community-based care among persons recently released from a correctional facility in Washington, DC: a pilot study","volume":"23","author":"Kuo","year":"2019","journal-title":"AIDS Behav"},{"key":"10.1016\/j.idc.2024.06.003_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/PPA.S236794","article-title":"Feasibility and acceptability of an mHealth-based approach as an HIV prevention strategy among people who use drugs on pre-exposure prophylaxis","volume":"14","author":"Shrestha","year":"2020","journal-title":"Patient Prefer Adherence"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552024000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T11:19:15Z","timestamp":1728299955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552024000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0891552024000370"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2024.06.003","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV and Substance Use Disorders","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}